Orphazyme: Eyeing a Secondary Listing in the US

Research Note

2020-07-01

13:32

Earlier today, we learned that Orphazyme had submitted a draft registration statement for a potential public offering in the United States. Orphazyme’s shares will continue to trade on Nasdaq Copenhagen. Naturally, we welcome this news. By allowing its shares to trade in the US, the company will increase its access to US investors. We also believe this could have a positive effect on the company’s valuation. We look forward to learning about this progress continuously during the second half of 2020.

AH

Anders Hedlund

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.